Ulcerative colitis: current pharmacotherapy and future directions

Bibliography

• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-7
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-53
   PubMed Web of Science ®Google Scholar
• Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006;12:979-94
   PubMed Web of Science ®Google Scholar
• Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-5
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing- ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011;33:672-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Regula J, Feagan BG, et al. Delayed- release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934-43. e1-3
   PubMedGoogle Scholar
• Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962;2:1708-11
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217-22
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962;2:441-3
   PubMedGoogle Scholar
• Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut 2011;60:130-3
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70
   PubMed Web of Science ®Google Scholar
• Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40-1
   PubMed Web of Science ®Google Scholar
• Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10
   PubMed Web of Science ®Google Scholar
• Bossa F, Fiorella S, Accadia L, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007;102:601-8
   PubMed Web of Science ®Google Scholar
• Mañosa M, Cabré E, Garcia-Planella E, et al. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids. Inflamm Bowel Dis 2011;17:2497-502
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010(10):CD007698
   PubMedGoogle Scholar
• Campieri M, Adamo S, Valpiani D, et al. Oral beclomethasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17:1471-80
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce, remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143:1218-26. e1-2
   PubMed Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433-41
   PubMed Web of Science ®Google Scholar
• Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:141-6
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330(26):1841-5
   PubMed Web of Science ®Google Scholar
• D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120(6):1323-9
   PubMed Web of Science ®Google Scholar
• Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005(1):CD004277
   PubMedGoogle Scholar
• Van Assche G, D’Haens G, Noman M, et al. Randomized double-blind comparison of 4mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31
   PubMed Web of Science ®Google Scholar
• Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-93
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Cyclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380(9857):1909-15
   PubMed Web of Science ®Google Scholar
• Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6:1112-16
   PubMed Web of Science ®Google Scholar
• Sharkey L, Bredin F, Nightingale A, et al. The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: long term outcomes. J Crohn Colitis 2011;5:91-4
   PubMed Web of Science ®Google Scholar
• Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62
   PubMed Web of Science ®Google Scholar
• Navas-Lopez VM, Blasco Alonso J, Serrano Nieto MJ, et al. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. J Crohn Colitis 2014;8:64-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. Erratum in N Engl J Med 2006;354:2200
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48:297-308
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400
   PubMed Web of Science ®Google Scholar
• Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7
   PubMedGoogle Scholar
• Vecchi M, Vernia P, Riegler G, et al. Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be? Clin Exp Gastroenterol 2013;6:1-7
   PubMedGoogle Scholar
• C Leitner G, Worel N, Vogelsang H. Selecive Granulocyte and Monocyte Apheresis as a non- pharmacological opinion for patients with inflammatory bowel disease. Transfus Med Hemother 2012;39:246-52
   PubMedGoogle Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544
   PubMedGoogle Scholar
• Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. Inflamm Bowel Dis 2013;19:2031-40
   PubMed Web of Science ®Google Scholar
• Sebastian S, Hernández V, Myrelid P, et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis 2014;8:5-18
   PubMed Web of Science ®Google Scholar
• Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology 2006;130:1941-9
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: special situation. J Crohns Colitis 2012;6(10):991-1030
   PubMedGoogle Scholar
• Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-8
   PubMedGoogle Scholar
• Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41
   PubMed Web of Science ®Google Scholar
• Lennard L. The clinical pharmacology of 6-mercaptupurine. Eur J Clin Pharmacol 1992;43:329-39
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166-75
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996;71(1):69-80
   PubMed Web of Science ®Google Scholar
• Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110(5):1416-21
   PubMed Web of Science ®Google Scholar
• El-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2009(3):CD007560
   PubMedGoogle Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 2014;146:681-8
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013;19:1700-9
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus Kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24
   PubMed Web of Science ®Google Scholar
• Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 2011;140:1838-46
   PubMed Web of Science ®Google Scholar
• Metha SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97
   PubMedGoogle Scholar
• Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. Aliment Pharmacol Ther 2013;37:855-66
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opin Emerg Drugs 2012;17:449-67
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analyis of changes in disease activity over years. Gastroenterology 1994;107:3-11
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population- based inception cohort (IBSEN study). Scand J Gastroenterol 2009;44:431-40
   PubMed Web of Science ®Google Scholar
• Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-63
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-9
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, D’Haens G, et al. One-year maintenance outcomes among patients with moderately- to- severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204-13
   PubMed Web of Science ®Google Scholar
• David T, Rubin DT, Dubinsky MC, et al. The impact of ulcerative colitis on patients’ lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2010;55:1044-52
   PubMedGoogle Scholar
• Hoivik ML, Moum B, Solberg IC, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 2013;62:368-75
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483-9
   PubMed Web of Science ®Google Scholar